Frontline CD38-Directed Therapy in Newly Diagnosed Multiple Myeloma

In this segment, Dr. Peter Voorhees introduces the Targeted™ Oncology Investigator Perspectives program and outlines the evolving treatment landscape in newly diagnosed multiple myeloma, including the movement of novel therapies into earlier lines of treatment. Dr. Doris Hansen and Dr. Luciano Costa introduce themselves before Dr. Voorhees turns to the role of CD38 monoclonal antibody-based therapy in newly diagnosed multiple myeloma. Dr. Costa discusses how treatment approaches have increasingly converged across transplant-eligible and transplant-ineligible patients, with CD38-directed therapy becoming an important component of frontline treatment. He describes the evolution from quadruplet regimens for transplant-eligible patients and triplet approaches for older or transplant-ineligible patients toward a more unified treatment paradigm. Dr. Costa also provides context for how evidence from randomized studies has demonstrated improvements in response depth, durability, progression-free survival, and overall survival with CD38-based therapy in transplant-ineligible patients. The discussion highlights how treatment selection and transplant decisions can increasingly be considered as related but distinct clinical decisions.